SCHEMBL4672707

SCHEMBL4672707

COc1cccc(Sc2ccc(C(=O)C=C(O)c3nc[nH]n3)o2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.46
EDNRA P25101 3/20 0.39
SLC9A1 P19634 1/20 0.36
MAOB P27338 1/20 0.36
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
NOTUM Q6P988 1/20 0.34
LMNA P02545 1/20 0.34
MTNR1A P48039 2/20 0.34
MTNR1B P49286 2/20 0.34
NPC1 O15118 2/20 0.34
TERT O14746 1/20 0.34
MAPT P10636 1/20 0.34
KDM4E B2RXH2 1/20 0.34
EDNRB P24530 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
C3AR1 Q16581 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672384 0.88 ALDH1A1 (0.41) PTPN11ALDH1A1HPGDLMNANPC1
SCHEMBL4673811 0.86 PTPN11 (0.43) PTPN11SLC9A1MAOBHPGDNOTUM
SCHEMBL27575898 0.85 PTPN11 (0.42) PTPN11EDNRASLC9A1MAOBALDH1A1
SCHEMBL4676271 0.85 EDNRA (0.38) PTPN11EDNRAMAOBALDH1A1NOTUM
SCHEMBL4672853 0.84 EDNRA (0.36) PTPN11EDNRAALDH1A1HPGDNOTUM
SCHEMBL4671076 0.84 ALDH1A1 (0.36) SLC9A1MAOBALDH1A1NOTUMLMNA
SCHEMBL4675827 0.82 MAPT (0.38) PTPN11ALDH1A1HPGDLMNAMAPT
SCHEMBL4671284 0.82 NR3C2 (0.40) MAOBALDH1A1HPGDLMNAMTNR1A
SCHEMBL4678887 0.81 PTPN11 (0.46) PTPN11ALDH1A1HPGDLMNAMTNR1A
SCHEMBL4678796 0.81 LMNA (0.38) SLC9A1MAOBALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTPN11 3101/4885EDNRA 1157/4885SLC9A1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.